Glomerular Disease
17
5
5
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
5.9%
1 terminated out of 17 trials
85.7%
-0.8% vs benchmark
12%
2 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (17)
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Pathogenesis of Glomerulosclerosis
Safety and Efficacy Study of VIS649 for IgA Nephropathy
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
Efficacy and Safety Study of HS-10542 for IgA Nephropathy
Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia
The Impact of Glomerular Disorders on Bone Quality and Strength
Podocyts Integrity in Glomerular Diseases
Effect of Moderate Caloric Restriction on Glomerular Growth After Kidney Transplantation
Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease
Effect of Glucocorticoids on Inflammation and Bone Metabolism in Patients With Glomerular Disease
KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
Kidney Disease Biomarkers
Vitamin D Supplementation in Glomerular Disease
TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)
Low Dose Steroids in the Treatment of Nephrotic Syndrome Relapse